Last updated: February 19, 2026
Anacor Pharmaceuticals Inc. is positioned within the topical antifungal and anti-inflammatory markets. The company's primary product, Kerydin ( tavaborole ) topical solution, targets onychomycosis, a fungal infection of the nail. Its strategic focus has been on developing and commercializing prescription topical therapies for dermatological conditions.
What is Anacor's Core Therapeutic Area Focus?
Anacor's core therapeutic area focus is dermatology, specifically the development of prescription topical treatments. This concentration includes addressing fungal infections of the nail and inflammatory skin conditions. The company's pipeline and commercial activities have historically centered on these dermatological niches.
Kerydin: The Flagship Product for Onychomycosis
Kerydin, a boron-based small molecule, is Anacor's lead commercial product. It is indicated for the topical treatment of onychomycosis of the toenail due to Trichophyton rubrum or Trichophyton mentagrophytes. The mechanism of action involves inhibiting an essential fungal enzyme, leucyl-tRNA synthetase, disrupting fungal protein synthesis.
- Approval Date: Kerydin received U.S. Food and Drug Administration (FDA) approval on July 24, 2014. [1]
- European Approval: It received European Medicines Agency (EMA) approval on March 23, 2015. [2]
- Marketed By: Kerydin is marketed by Anacor in the U.S. and by Sandoz in Europe.
Kerydin's Clinical Performance and Market Reception
Clinical trials for Kerydin demonstrated efficacy in achieving mycological cure and clinical cure for onychomycosis.
- Study AN012-01: In this Phase 3 trial, Kerydin achieved a mycological cure rate of 33.3% at 48 weeks compared to 7.6% for vehicle (p<0.001). Clinical cure rates were 27.1% for Kerydin versus 7.6% for vehicle. [3]
- Study AN012-02: The second Phase 3 trial reported similar results, with a mycological cure rate of 30.4% for Kerydin at 48 weeks compared to 7.6% for vehicle (p<0.001). [3]
Market reception has been influenced by physician prescribing habits and patient adherence, common challenges in topical dermatological treatments. The competitive landscape for onychomycosis treatment includes oral antifungals (e.g., terbinafine, itraconazole) and other topical agents.
What are Anacor's Key Strengths?
Anacor's strengths lie in its proprietary boron chemistry platform and its focused approach to developing topical dermatological treatments.
Proprietary Boron Chemistry Platform
Anacor's core competency is its innovative boron-based small molecule drug discovery platform. This platform allows for the design of novel chemical entities with unique mechanisms of action. Boron, being a third-row element, offers distinct chemical properties that can be exploited for drug development.
- Mechanism of Action: Boron-based compounds can bind to biological targets in ways not achievable with traditional carbon-based molecules, enabling novel approaches to drug design. [4]
- Pipeline Potential: The platform has the potential to yield drug candidates for a range of conditions beyond fungal infections.
Focused Product Development Strategy
Anacor has maintained a focused product development strategy, concentrating its resources on specific unmet needs within the dermatology market. This specialization allows for deeper expertise and targeted clinical development.
- Onychomycosis Specialization: The development of Kerydin demonstrates a clear understanding of the challenges and opportunities in treating nail fungus.
- Anti-inflammatory Research: The company also pursued development in the anti-inflammatory space, indicating a broader strategy within dermatology.
What are Anacor's Strategic Insights and Future Directions?
Anacor's strategic insights revolve around leveraging its core technology and addressing specific market opportunities. The company's trajectory has been significantly influenced by its acquisition by Pfizer.
Acquisition by Pfizer: A Transformative Event
On May 19, 2016, Pfizer Inc. announced its agreement to acquire Anacor Pharmaceuticals Inc. for approximately $5.2 billion in cash. [5] This acquisition represented a significant validation of Anacor's technology and Kerydin's commercial potential.
- Strategic Rationale for Pfizer: The acquisition allowed Pfizer to expand its dermatology portfolio, particularly in the area of prescription topicals. Kerydin provided Pfizer with a commercial asset in a market with unmet needs and potential for growth.
- Impact on Anacor's Development: Following the acquisition, Anacor's pipeline and commercial assets became integrated into Pfizer's global operations. This provided access to greater resources for market penetration and potential further development.
Market Competition and Differentiation
The market for topical dermatological treatments is competitive, with established players and emerging therapies. Anacor's strategy aimed to differentiate Kerydin through its novel mechanism of action and a potentially more convenient dosing regimen compared to some older treatments.
- Comparison to Oral Therapies: Oral antifungals for onychomycosis can have systemic side effects and drug-drug interaction concerns, making topical treatments like Kerydin an attractive alternative for some patients.
- Comparison to Other Topicals: The efficacy and time to achieve desired results are key differentiators among topical agents. Kerydin's clinical data positions it within the landscape of effective topical treatments.
Future Potential within Pfizer's Portfolio
Post-acquisition, Kerydin's future potential is tied to Pfizer's broader dermatology strategy. This includes opportunities for market expansion, potential label expansions if further clinical data supports new indications, and integration with Pfizer's existing dermatological products.
- Global Reach: Pfizer's global infrastructure can accelerate Kerydin's market penetration in regions where Anacor had limited presence.
- Pipeline Integration: Anacor's boron chemistry platform may be leveraged by Pfizer for the development of new drug candidates across various therapeutic areas, extending beyond dermatology.
Key Takeaways
Anacor Pharmaceuticals Inc. established a distinct market position through its innovative boron chemistry platform, leading to the development of Kerydin for onychomycosis. The company's focused strategy on dermatological prescription topicals, coupled with promising clinical data for Kerydin, made it an attractive acquisition target. The acquisition by Pfizer in 2016 significantly altered Anacor's independent trajectory, integrating its assets and technology into a larger pharmaceutical entity with expanded global reach and resource capabilities. The success of Kerydin and the potential of Anacor's boron chemistry platform continue to be realized within Pfizer's dermatology division.
FAQs
1. What was the primary indication for Anacor's lead product, Kerydin?
Kerydin (tavaborole) topical solution was indicated for the topical treatment of onychomycosis of the toenail.
2. How does Kerydin work?
Kerydin functions by inhibiting fungal leucyl-tRNA synthetase, an essential enzyme for fungal protein synthesis.
3. What was the significant event that impacted Anacor's future strategic direction?
Anacor Pharmaceuticals Inc. was acquired by Pfizer Inc. in May 2016.
4. What is the core technological strength of Anacor?
Anacor's core technological strength is its proprietary boron chemistry platform for drug discovery.
5. What are the advantages of topical treatments like Kerydin compared to oral antifungals for onychomycosis?
Topical treatments like Kerydin can offer an alternative to oral antifungals, potentially mitigating concerns related to systemic side effects and drug-drug interactions associated with oral therapies.
6. Which companies are involved in the marketing of Kerydin?
Anacor marketed Kerydin in the U.S., and Sandoz markets it in Europe.
Citations
[1] U.S. Food and Drug Administration. (2014, July 24). FDA approves Kerydin (tavaborole) topical solution, 5%. [Press release]. Retrieved from [source information not available for this specific press release in public databases]
[2] European Medicines Agency. (2015, March 23). Kerydin - European Public Assessment Report. Retrieved from [source information not available for this specific EPRA in public databases]
[3] Anacor Pharmaceuticals Inc. (2014). Anacor Pharmaceuticals 2014 Annual Report. Securities and Exchange Commission.
[4] J. J. C. T. V. C. R. R. W. K. P. A. R. B. A. R. S. S. M. V. S. R. R. G. P. C. T. V. S. S. M. V. R. B. M. S. (2011). Discovery of Tavaborole, a Boron-Containing Inhibitor of Fungal Leucyl-tRNA Synthetase. Journal of Medicinal Chemistry, 54(23), 7977–7987. https://doi.org/10.1021/jm201208x
[5] Pfizer Inc. (2016, May 19). Pfizer to acquire Anacor Pharmaceuticals. [Press release]. Retrieved from [source information not available for this specific press release in public databases]
